Julia Sousa Lins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julia Sousa Lins has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Mendes Awni Cidale
Department of Oncology, Hospital Sirio-Libanes, Sao Paulo, SP, Brazil
1 shared publication - Eduardo Felício de Campos
Hospital Sirio Libanês, Oncologia Clínica
1 shared publication - Eduardo Hiroshi Akaishi
Hospital Sirio Libanês, Oncologia Clínica
1 shared publication - Fabio de Oliveira Ferreira
Cutaneous Malignancies and Sarcomas Group, Hospital Sírio Libanês, São Paulo, Brazil
1 shared publication - Fernanda Cunha Capareli
Hospital Sirio Libanês, Oncologia Clínica
1 shared publication - Frederico Teixeira
Hospital Sirio Libanês, Oncologia Clínica
1 shared publication
Latest Publications
- Open Access
- 16 May 2024
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 20 (CP) , 1-18
Gastrointestinal stromal tumors: advances in molecular characterization and therapeutic implications
Recognition of the molecular basis of gastrointestinal stromal tumors has paved the way for significant breakthroughs in the diagnosis and treatment of this disease as well as positioned gastrointestinal stromal tumors as a framework for the concept of precision oncology in solid tumors. The incorporation of novel targeted agents for molecularly defined subgroups has led to significant improvements in treatment outcomes; however, the characterization of heterogeneous KIT or PDGFRA mutations and the emergence of resistance mechanisms highlight the need for a broader use of comprehensive molecular profiling and emphasize the importance of molecularly driven adaptive treatment strategies. Such a molecular background is critical for developing personalized and effective interventions and optimizing outcomes. The present review summarizes key studies that provide the basis for standard-of-care management options as well as provides molecular insights into the management of gastrointestinal stromal tumors, with an emphasis on recent advances.
- 16 May 2024
- Published by Georg Thieme Verlag KG in Brazilian Journal of Oncology
- Vol. 20 (CP) , 1-18
Open AccessGastrointestinal stromal tumors: advances in molecular characterization and therapeutic implications
Recognition of the molecular basis of gastrointestinal stromal tumors has paved the way for significant breakthroughs in the diagnosis and treatment of this disease as well as positioned gastrointestinal stromal tumors as a framework for the concept of precision oncology in solid tumors. The incorporation of novel targeted agents for molecularly defined subgroups has led to significant improvements in treatment outcomes; however, the characterization of heterogeneous KIT or PDGFRA mutations and the emergence of resistance mechanisms highlight the need for a broader use of comprehensive molecular profiling and emphasize the importance of molecularly driven adaptive treatment strategies. Such a molecular background is critical for developing personalized and effective interventions and optimizing outcomes. The present review summarizes key studies that provide the basis for standard-of-care management options as well as provides molecular insights into the management of gastrointestinal stromal tumors, with an emphasis on recent advances.